Ann: Institutional Placement and proposed Share Purchase Plan SPP, page-4

Well over $8 m raised...that's nice..

Obviously not relying on the SPP....anything there will be a bonus but as per HC discussions , most will take up the SPP.

This quote pretty much sums up the investment in ANP for the next few months / years...

Obviously life changing if the drug shows what it's capable of in one ongoing trial...

The new funds will allow us to continue thedevelopment of our clinical programs, in particular funding the ongoing international Phase IIb Clinical
Trial program for ATL1102 in Duchenne muscular dystrophy, as well as for ongoing working capital.
The next 12-18 months are an exciting and busy time with results from the mdx DMD mouse study
anticipated in July ‘23, the Limb Girdle R2 Dystrophy animal study in August ‘23, the 9-month chronic
toxicology study around May ’24 and the clinical study primary endpoint readout anticipated July ’24”.


Glh...imo dyor